Immune-related adverse events after 2 years in patients with advanced non-small-cell lung cancer receiving extended immune checkpoint inhibitor therapy.

被引：0
|
作者：
Elghawy, Omar
Barsouk, Adam
Sussman, Jonathan Henry
Davella, Christopher
Singh, Aditi Puri
Ciunci, Christine Agnes
Robinson, Kyle William
Kosteva, John A.
Langer, Corey J.
Cohen, Roger B.
Aggarwal, Charu
Marmarelis, Melina Elpi
Sun, Lova
机构：
[1] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[2] Univ Penn, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8551
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Pancreatic Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Therapy
    Patel, Vanisha
    Ashkar, Motaz
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S714 - S714
  • [32] Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy
    Saliba, Antoine N.
    Xie, Zhuoer
    Higgins, Alexandra S.
    Andrade-Gonzalez, Xavier A.
    Fuentes-Bayne, Harry E.
    Hampel, Paul J.
    Kankeu Fonkoua, Lionel A.
    Childs, Daniel S.
    Rakshit, Sagar
    Bezerra, Evandro D.
    Kommalapati, Anuhya
    Lou, Yanyan
    Rivera, Candido E.
    Price, Katharine A.
    Chintakuntlawar, Ashish
    Yan, Yiyi
    Schwecke, Anna J.
    Block, Matthew S.
    Thanarajasingam, Uma
    Thanarajasingam, Gita
    Wolanskyj-Spinner, Alexandra P.
    Marshall, Ariela L.
    Kottschade, Lisa A.
    Go, Ronald S.
    Al-Kali, Aref
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (10) : E362 - E367
  • [33] Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy
    Zhou, Nanruoyi
    Velez, Maria A.
    Owen, Dwight
    Lisberg, Aaron E.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (09): : 1287 - 1290
  • [34] Immune-related adverse events (IrAEs) in patients receiving immune checkpoint inhibitors
    Ferrarini, Alessia
    Benfaremo, Devis
    Rossetti, Giulia
    Morgese, Francesca
    Pomponio, Giovanni
    Berardi, Rossana
    Gabrielli, Armando
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18
  • [35] Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
    Allouchery, Marion
    Lombard, Thomas
    Martin, Mickael
    Rouby, Franck
    Sassier, Marion
    Bertin, Celia
    Atzenhoffer, Marina
    Miremont-Salame, Ghada
    Perault-Pochat, Marie-Christine
    Puyade, Mathieu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [36] Longitudinal immune and genomic monitoring reveals signatures of response and Immune-related adverse events in cancer patients receiving checkpoint inhibitor therapy
    Khan, Shaheen
    Gerber, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [37] Immune-related adverse events and symptom burden in patients with melanoma receiving adjuvant immune checkpoint inhibitor
    Abdel-Wahab, Noha
    Kus, Teresa
    Bentebibel, Salah-Eddine
    McQuade, Jennifer Leigh
    Glitza, Isabella Claudia
    Amaria, Rodabe Navroze
    Patel, Sapna Pradyuman
    Wong, Michael K. K.
    Tawbi, Hussein A.
    Davies, Michael A.
    Peterson, Susan K.
    Shete, Sanjay
    Yee, Cassian
    Kavelaars, Annemieke
    Suarez-Almazor, Maria E.
    Diab, Adi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
    Shankar, Bairavi
    Zhang, Jiajia
    Naqash, Abdul Rafeh
    Forde, Patrick M.
    Feliciano, Josephine L.
    Marrone, Kristen A.
    Ettinger, David S.
    Hann, Christine L.
    Brahmer, Julie R.
    Ricciuti, Biagio
    Owen, Dwight
    Toi, Yukihiro
    Walker, Paul
    Otterson, Gregory A.
    Patel, Sandip H.
    Sugawara, Shunichi
    Naidoo, Jarushka
    JAMA ONCOLOGY, 2020, 6 (12) : 1952 - 1956
  • [39] Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge
    Liu, Jie
    Yu, Jinming
    Meng, Xue
    JAMA ONCOLOGY, 2020, 6 (11) : 1813 - +
  • [40] Role of Immune-Related Adverse Events (irAEs) and Albumin in Non-Small-Cell Lung Cancer (NSCLC)
    Bawek, S.
    Kalvapudi, S.
    Vedire, Y.
    Pachimatla, A.
    Jain, P.
    Yendamuri, S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S612 - S613
12345